Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Cibus Appoints Rosa Cheuk Kim as Vice President, Legal


Cibus, a pioneer of precision gene editing in agriculture, today announced the appointment of former Internal Counsel, Rosa Cheuk Kim, to Vice President, Legal. In her elevated role, Cheuk Kim will oversee all legal activities at Cibus, including intellectual property (IP), contracts and litigation.

"In working with internal and external counsel, Rosa has been a key driver in growing Cibus' IP portfolio for nearly a decade," said Greg Gocal, Ph.D., CSO and EVP of Cibus. "Over many years, she has thoughtfully managed our IP strategy, from overseeing our internal discovery disclosure process to protecting those discoveries as patents and trade secrets covering key areas that include what to edit, how to edit, cell culture and automation. We appreciate her commitment to Cibus and her attention to detail. I look forward to seeing the continued, impressive impact she will have in her new position."

Cheuk Kim has played a critical role in positioning Cibus as a leading company in gene editing for agricultural crops and microorganisms used in fermentation. Prior to her role as Vice President, Legal, Cheuk Kim served as Cibus' Patent Counsel for nearly 10 years, playing a key role in developing and extending Cibus' extensive IP portfolio. Before her time at Cibus, Cheuk Kim served as a patent attorney at Foley & Lardner LLP. Prior to entering the legal profession, for nearly eight years Cheuk Kim gained invaluable experience in molecular biology research in Dr. Joseph Ecker's Lab at the Salk Institute and previously at the University of Pennsylvania. Cheuk Kim received her J.D. from the University of San Diego School of Law. Cheuk Kim earned both a Master of Science in biotechnology and a Bachelor of Arts in biology from the University of Pennsylvania.

"Throughout almost a decade at Cibus, it has been incredibly rewarding to support the company's mission of innovating agriculture toward a more sustainable future," said Cheuk Kim. "Cibus' pipeline of plant traits ? contained within our IP portfolio ? has the potential to make agriculture a more environmentally- and economically-viable practice. I appreciate the opportunity to continue supporting this bold global vision as we continue expanding into the field and the market."

About Cibus

Cibus is a leading AgTech company that uses precision gene editing technologies to develop novel traits for the global agricultural seed industry. Cibus' business is based on developing Input and Agronomic Traits that make farming more profitable and sustainable by lowering the cost of farming, improving productivity, and simplifying farmers' work. Cibus' business model is built around earning license fees or trait royalties by broadly licensing its high value traits to seed companies that incorporate Cibus traits into their elite seed varieties. Cibus is focused on the world's largest crops: Canola, Rice, Potato, Soybean, Wheat and Corn which, globally, represent billions of cultivated acres. It already has developed and begun commercializing high value traits for Canola and is actively working to develop a growing pipeline of traits in numerous crops. Cibus' core technology, its Rapid Trait Development System (RTDStm), is a leading technological platform in the Post-GMO revolution that develops traits that are "nature identical" and does not use foreign material such as transgenes or recombinant DNA. RTDS represents a broad family of patented biological and data science technologies. An important strength of RTDS is that it will increase the speed of innovation in farming and, in the process, adding back diversity towards developing numerous valuable traits, single or stacked, available to the farming industry. The company has subsidiaries in Europe and North America and a state-of-the-art research and development center in San Diego, California.


These press releases may also interest you

at 20:42
OncoSec Medical Incorporated (the "Company" or "OncoSec") today announced that it intends to offer and sell shares of its common stock in a public offering. The offering is subject to market conditions, and there can be no assurance as to whether or...

at 20:36
Swiss biotech company Memo Therapeutics AG (MTx) and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership to manufacture MTx's therapeutic COVID-19...

at 19:01
Aurora Recovery Centre has upped its game once again. With laser focus on moving forward in reshaping the face of treatment and...

at 18:20
Resverlogix Corp. ("Resverlogix" or the "Company") announced today it has closed a private placement of 3,573,333 equity units at a price of $0.75 per unit for gross proceeds of approximately $2.7 million (US$2.0 million). Each unit was comprised of...

at 17:55
Command Medical Products is pleased to announce Thomas Black as Command Medical Products' new business development manager. Mr....

at 17:51
This week, 6-year-old Ellie York of Tampa and her family joined more than 50 other pediatric patients from across the nation in meeting with their members of Congress to speak out on behalf of children with complex medical conditions....



News published on 13 july 2020 at 08:05 and distributed by: